바이오테크 보도자료
-
- Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
- Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 ...
- 2021년 04월 23일
-
- BIO KOREA 2021 International Convention Is Ready - Showing What Makes Korea’s Bio-health Market at Record High
- The 16th edition of BIO KOREA, the reference B2B event for global biotech and health industry professionals interested in opportunities in the Asian region, will be held online from 9th to 21st June 2021 wit...
- 2021년 04월 22일
-
- Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenz...
- 2021년 04월 22일
-
- MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
- MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the l...
- 2021년 04월 22일
-
- New gPROMS Process - Process Modelling and Optimization for the Digital World
- Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment. Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the fi...
- 2021년 04월 21일
-
- PTT Invests in Lotus Pharmaceutical's Strategic Partnership in South East Asia
- Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be acquired by Innobic (Asia). T...
- 2021년 04월 20일
-
- Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenz...
- 2021년 04월 20일
-
- ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers
- ROSALIND®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based technology providers to enable a powerful ne...
- 2021년 04월 16일
-
- Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules f...
- 2021년 04월 15일
-
- RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
- RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Z...
- 2021년 04월 14일
전시회
